Immune regulatory antibodies: Are they the next advance?

Cancer Journal

Volumn 16, Issue 4, 2010, Pages 311-317

  Wolchok, Jedd D ^a   Yang, Arvin S ^a   Weber, Jeffrey S ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Antibody; Checkpoint; Immune; Stimulation; T cell

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BUDESONIDE; CALL ANTIBODY; CARBOPLATIN; CD137 ANTIGEN; CD40 ANTIBODY; CD40 ANTIGEN; CP 870893; CT 011; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 2; IPILIMUMAB; MDX 1105; MDX 1106; PACLITAXEL; PEPTIDE VACCINE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; SGN 40; TEMOZOLOMIDE; TICILIMUMAB; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR OX 40 ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTHRITIS; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; COLITIS; COLON CANCER; COLON CARCINOMA; CONJUNCTIVITIS; CORTICOSTEROID THERAPY; CYTOKINE RELEASE SYNDROME; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOCRINE DISEASE; FATIGUE; FEVER; FIBROSARCOMA; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNOREGULATION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER FUNCTION TEST; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MELANOMA; METASTASIS; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREATITIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN FUNCTION; PRURITUS; RASH; REVIEW; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; VITILIGO;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77958018335     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181eb3381     Document Type: Review

References (95)

1. Alegre ML, Noel PJ, Eisfelder BJ, et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol. 1996;157:4762-4770.
2. Linsley PS, Bradshaw J, Greene J, et al. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity. 1996;4:535-543.
3. Chuang E, Lee KM, Robbins MD, et al. Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases. J Immunol. 1999;162:1270-1277.
4. Cinek T, Sadra A, Imboden JB. Cutting edge: tyrosine-independent transmission of inhibitory signals by CTLA-4. J Immunol. 2000;164:5-8.
5. Carreno BM, Bennett F, Chau TA, et al. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol. 2000;165:1352-1356.
6. van der Merwe PA, Bodian DL, Daenke S, et al. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med. 1997;185:393-403.
7. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229:12-26.
8. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405-413.
9. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985-988.
10. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541-547.
11. + T cells. Immunity. 1997;7:885-895.
12. + T cells. Eur J Immunol. 1998;28:3137-3143.
13. Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4 (+) T cell responses. Proc Natl Acad Sci USA. 1999;96:8603-8608.
14. Greenwald RJ, Boussiotis VA, Lorsbach RB, et al. CTLA-4 regulates induction of anergy in vivo. Immunity. 2001;14:145-155.
15. Greenwald RJ, Oosterwegel MA, van der Woude D, et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol. 2002;32:366-373.
16. McCoy KD, Hermans IF, Fraser JH, et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8 (+) T cells independently of CD4 (+) T cell help. J Exp Med. 1999;189:1157-1162.
17. Perez VL, Van Parijs L, Biuckians A, et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 1997;6:411-417.
18. + T-cell dependent. Blood. 2006;108:3818-3823.
19. + regulatory T cell function. Science. 2008;322:271-275.
20. Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science. 2006;313:1972-1975.
21. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734-1736.
22. Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA. 1997;94:8099-8103.
23. Yang YF, Zou JP, Mu J, et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 1997;57:4036-4041.
24. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190:355-366.
25. Hurwitz AA, Yu TF, Leach DR, et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA. 1998;95:10067-10071.
26. Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000;60:2444-2448.
27. van Elsas A, Sutmuller RP, Hurwitz AA, et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med. 2001;194:481-489.
28. Davila E, Kennedy R, Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003;63:3281-3288.
29. Gregor PD, Wolchok JD, Ferrone CR, et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004;22:1700-1708.
30. + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207:637-650.
31. Demaria S, Bhardwaj N, McBride WH, et al. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005;63:655-666.
32. Mokyr MB, Kalinichenko T, Gorelik L, et al. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumorbearing mice. Cancer Res. 1998;58:5301-5304.
33. Mokyr MB, Kalinichenko TV, Gorelik L, et al. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor. J Immunol. 1998;160:1866-1874.
34. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol. 2005;23:8968-8977.
35. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372-8377.
36. Ribas A. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675, 206). Oncologist. 2008;13(Suppl 4):10-15.
37. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist. 2008;13(Suppl 4):16-25.
38. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30:825-830.
39. Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane as novel immunotherapy for patients with advanced breast cancer (meeting abstracts). J Clin Oncol. 2009;27:abstract 3034.
40. Slovin SF, Beer TM, Higano CS, et al. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) (meeting abstracts). J Clin Oncol. 2009;27:abstract 5138.
41. Reuben JM, Lee BN, Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006;106:2437-2444.
42. Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009;27:1075-1081.
43. Ribas A, Comin-Anduix B, Chmielowski B, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009;15:6267-6276.
44. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043-6053.
45. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100:4712-4717.
46. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2009;11:155-164.
47. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. Epub February 10, 2010.
48. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med. Epub June 14, 2010.
49. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-7420.
50. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28:593-598.
51. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591-5598.
52. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005-1016.
53. Hersh EM, Weber JS, Powderly JD, et al. Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX-010) with or without dacarbazine (meeting abstracts). J Clin Oncol. 2008;26: abstract 9022.
54. Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009;69:609-615.
55. Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009;15:6446-6453.
56. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113:1581-1588.
57. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-1034.
58. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from the host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293-12297.
59. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089-1093.
60. Azuma T, Yao S, Zhu G, et al. B7-H1 is a ubiquitous anti-apoptotic receptor on cancer cells. Blood. 2008;111:3635-3643.
61. Parekh VV, Lalani S, Kim S, et al. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol. 2009;182:2816-2826.
62. Talay O, Shen CH, Chen L, et al. B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation. Proc Natl Acad Sci USA. 2009;106:2741-2746.
63. + regulatory T cells. Proc Natl Acad Sci USA. 2008;105:9331-9336.
64. + T lymphocytes are prognostic factors in human ovarian cancer. Proc Natl Acad Sci USA. 2007;194:3360-3365.
65. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Can Res. 2007;13:2151-2157.
66. Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116:1757-1766.
67. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141-151.
68. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319-322.
69. Wong RM, Scotland RR, Lau RL, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigenspecific CTLs. Int Immunol. 2007;19:1223-1228.
70. + T cells. J Immunol. 2009;182:5240-5249.
71. Curran MA, Monatalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010;107:4275-4280.
72. Li B, Van Roey M, Wang C, et al. Anti-programmed death-1 synergizes with granulocyte macrophage colony stimulating factor secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Can Res. 2009;15:1632-1634.
73. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14:3044-3051.
74. Brahmer JR, Toplian SL, Wollner I. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol. 2008;26(suppl): abstract 3006.
75. Brahmer JR, Topalian SL, Powderly J, et al. Phase II experience with MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol. 2008;27(suppl): abstract 3015.
76. Zhang L, Gajewski T, Kline J. PD-1/PD-L1 interactions inhibit anti-tumor responses in a murine acute myeloid leukemia model. Blood. 2009;114:1545-1552.
77. +CTL to cause tumor eradication. J Immunol. 2004;173:6753-6759.
78. van Mierlo GJ, den Boer AT, Medema JP, et al. CD40 stimulation leads to effective therapy of CD40 (-) tumors through strong induction of systemic cytolytic T lymphocyte immunity. Proc Natl Acad Sci USA. 2002;99:5561-5566.
79. Sotomayor EM, Borello I, Tubb E, et al. Conversion of tumor specific CD4 T cell tolerance to T cell priming through in vivo ligation of CD40. Nat Med. 1999;5:780-787.
80. Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med. 1999;5:774-779.
81. Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2010;70:99-108.
82. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876-883.
83. Advani R, Forero-Torres A, Furman RR, et al. Phase I study of the humanized anti-CD40 antibody dacetuzumab in refractory or recurrent non-Hoidgkin's lymphoma. J Clin Oncol. 2009;27:4371-4377.
84. Redmond WL, Gough MJ, Charbonneau B, et al. Defects in the acquisition of T cell effector function after priming with tumor or soluble antigen can be overcome by the acquisition of an OX-40 agonist. J Immunol. 2007;179:7244-7263.
85. Kjaergaard J, Tanaka J, Kim JA, et al. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000;60:5514-5521.
86. Weinberg AD, Rivera MM, Prell R, et al. Engagement of the OX-40 receptor in vivo enhances anti-tumor-immunity. J Immunol. 2000;164:2160-2169.
87. + T cell mobilization/memory development and humoral immunity: comparison of αOX-40 with αCTLA-4. J Immunol. 2001;167:6804-6811.
88. Kovacsovics-Bankowski M, Walker E, Floyd K, et al. Increased CD4 and CD8 memory T cell proliferation following anti-OX40 administration to cancer patients: immunologic assessment of a phase I clinical trial. ISBtC 2009.
89. Kim YH, Choi BK, Kim KH, et al. Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatininduced nephrotoxicity. Cancer Res. 2008;68:7264-7269.
90. + cytotoxic T lymphocytes for adoptive immunotherapy. J Immunol. 2007;179:4910-4918.
91. Kocak E, Lute K, Chang X, et al. Combination therapy with anti-CTL antigen-4 and anti-41-BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 2006;66:7276-7284.
92. Miller RE, Jones J, Le T, et al. 4-1BB specific monoclonal antibody promotes the generation of tumor specific immune responses by direct activation of CD8 T cells in a CD40 dependent manner. J Immunol. 2003;169:1792-1800.
93. + T cells. Cancer Res. 2002;62:3459-3465.
94. Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol. 2008;26(20 suppl): abstract 3007.
95. Sznol M, Powderly JD, Smith DC, et al. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol. 2010;28(suppl): abstract 2506.